$5.04
3.26%
Nasdaq, Fri, Sep 25 2026.
ISIN
US68236V1044
Symbol
ATNF

180 Life Sciences Corp Stock price

$5.04
-0.85 14.36% 1M
+2.05 68.56% 6M
+0.14 2.86% YTD
-18.26 78.37% 1Y
-101.36 95.26% 3Y
-21,920.96 99.98% 5Y
-36,854.96 99.99% 10Y
-36,854.96 99.99% 20Y
Nasdaq, Closing price Fri, Sep 25 2026
-0.17 3.26%
ISIN
US68236V1044
Symbol
ATNF
Industry

Is 180 Life Sciences Corp a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,127 stocks worldwide.

Key metrics

Basic
Market capitalization
-
Enterprise Value
-
Net debt
positive
Cash
$2.2m
Shares outstanding
6.0m
Valuation (TTM | estimate)
P/E
negative
P/S
- | -
EV/Sales
- | -
EV/FCF
-
P/B
-
Financial Health
Equity Ratio
72.5%
Return on Equity
-153.3%
ROCE
-149.0%
ROIC
-167.0%
Debt/Equity
0.3
Financials (TTM | estimate)
Revenue
$0.0 | $13.1m
EBITDA
$-8.0m
EBIT
$-8.0m
Net Income
$-17.2m
Free Cash Flow
$-3.2m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
54.8%
EBIT
54.9%
Net Income
-37.2%
Free Cash Flow
25.7%
Margin
Gross
-
EBITDA
-
EBIT
-
Net
-
Free Cash Flow
-
More
EPS
$-3.0
FCF per Share
$-0.5
Short interest
47.2%
Employees
4
Rev per Employee
$0.0

180 Life Sciences Corp Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a 180 Life Sciences Corp forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a 180 Life Sciences Corp forecast:

Buy
86%
Hold
14%

Financial data from 180 Life Sciences Corp

Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 4.98 4.98
26% 26%
-
- Research and Development Expense 1.51 1.51
32% 32%
-
-8 -8
55% 55%
-
- Depreciation and Amortization 0.01 0.01
90% 90%
-
EBIT (Operating Income) EBIT -8.02 -8.02
55% 55%
-
Net Profit -17 -17
37% 37%
-

In millions USD.

Don't miss a Thing! We will send you all news about 180 Life Sciences Corp directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

180 Life Sciences Corp. develops pharmaceuticals for chronic pain and inflammatory diseases. It operates as a clinical-stage biotechnology company focused on the development of novel drugs that fulfil unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University. The company was founded in 2016 and is headquartered in Menlo Park, CA.

Head office United States
CEO Mr. Jordan
Employees 4
Founded 2016
Website 180lifesciences.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today